Travere Therapeutics, Inc.
Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare diseases. Driven by a mission to support and bring hope to the rare disease community, the company emphasizes patient-centered care, scientific innovation, and health equity. Their work spans therapeutic areas such as rare kidney and metabolic diseases, with a focus on improving diagnosis, access to care, and community support.
Industries
Nr. of Employees
medium (51-250)
Travere Therapeutics, Inc.
San Diego, California, United States, North America
Products
Sparsentan (therapy for glomerular disease)
Orally administered therapeutic evaluated and marketed for rare glomerular diseases; company lists regulatory submissions and approvals related to this compound for indications including IgA nephropathy and focal segmental glomerulosclerosis.
Tiopronin delayed‑release formulation (therapy for cystinuria)
Oral formulation used to reduce cystine stone formation in individuals with cystinuria; company provides prescribing information and a patient support hub for this therapy.
Sparsentan (therapy for glomerular disease)
Orally administered therapeutic evaluated and marketed for rare glomerular diseases; company lists regulatory submissions and approvals related to this compound for indications including IgA nephropathy and focal segmental glomerulosclerosis.
Tiopronin delayed‑release formulation (therapy for cystinuria)
Oral formulation used to reduce cystine stone formation in individuals with cystinuria; company provides prescribing information and a patient support hub for this therapy.
Services
Patient support and access hub (TotalCare)
Centralized patient support offering insurance and reimbursement assistance, financial support options, counseling on therapy initiation, and a phone and online hub for patients and providers.
Investigator‑sponsored research (ISR) support
Grant funding, provision of clinical trial material, and administrative support for investigator-initiated studies aligned with company research priorities; application via a centralized grants portal.
Facilitated genetic testing programs
Programs that enable access to gene panel testing for specific rare disorders, offered through external clinical laboratories to assist diagnostic evaluation.
Facilitated biochemical diagnostic testing
Sponsorship or facilitation of biochemical assays for rare metabolic and liver disorders, including atypical bile acid profiling and measurement of disease-associated metabolites.
Biochemical CTX testing program
Lab-based biochemical testing to measure elevated disease-associated metabolites (e.g., 7a,12a-dihydroxy-4-cholesten-3-one) to assist diagnosis of cerebrotendinous xanthomatosis (CTX), provided at no cost to qualifying patients.
Patient support and access hub (TotalCare)
Centralized patient support offering insurance and reimbursement assistance, financial support options, counseling on therapy initiation, and a phone and online hub for patients and providers.
Investigator‑sponsored research (ISR) support
Grant funding, provision of clinical trial material, and administrative support for investigator-initiated studies aligned with company research priorities; application via a centralized grants portal.
Facilitated genetic testing programs
Programs that enable access to gene panel testing for specific rare disorders, offered through external clinical laboratories to assist diagnostic evaluation.
Facilitated biochemical diagnostic testing
Sponsorship or facilitation of biochemical assays for rare metabolic and liver disorders, including atypical bile acid profiling and measurement of disease-associated metabolites.
Biochemical CTX testing program
Lab-based biochemical testing to measure elevated disease-associated metabolites (e.g., 7a,12a-dihydroxy-4-cholesten-3-one) to assist diagnosis of cerebrotendinous xanthomatosis (CTX), provided at no cost to qualifying patients.
Expertise Areas
- Clinical development for rare disease therapies
- Regulatory strategy and submissions (FDA, EU)
- Rare kidney disease (glomerular disorders) therapeutics
- Rare metabolic disease therapeutics
Key Technologies
- Whole genome sequencing (WGS) for newborn screening
- Gene panel sequencing
- Targeted biochemical assays for bile acids and disease metabolites
- Mass spectrometry-based metabolite measurement